Meeting
2020 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
Authors
Scott S. Tykodi
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA
Scott S. Tykodi , Todd Michael Bauer , David F. McDermott , Edward Arrowsmith , Naseem J. Zojwalla , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03634540
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS766)
Abstract #
TPS766
Poster Bd #
K22
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.
First Author: Toni K. Choueiri
Poster
2020 ASCO Virtual Scientific Program
Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Toni K. Choueiri
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang
Poster
2023 ASCO Annual Meeting
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
First Author: David F. McDermott